according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 6029721-00013 Date of first issue: 10.06.2020 4.1

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Abamectin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-: Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company **MSD**

Kilsheelan

Clonmel Tipperary, IE

Telephone 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4 H332: Harmful if inhaled.

Specific target organ toxicity - repeated H373: May cause damage to organs through pro-

exposure, Category 2 longed or repeated exposure.

Short-term (acute) aquatic hazard, Cate-H400: Very toxic to aquatic life.

gory 1

Long-term (chronic) aquatic hazard, Cat-H410: Very toxic to aquatic life with long lasting

egory 1

effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms





according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 6029721-00013 Date of first issue: 10.06.2020

Signal word : Warning

Hazard statements : H332 Harmful if inhaled.

H373 May cause damage to organs through prolonged

or repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P271 Use only outdoors or in a well-ventilated area.

P273 Avoid release to the environment.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh

air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.

P314 Get medical advice/ attention if you feel unwell.

P391 Collect spillage.

Hazardous components which must be listed on the label:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No.	Classification	Concentration (% w/w)
	Index-No.		
	Registration number		
abamectin (combination of aver-	71751-41-2	Acute Tox. 2; H300	>= 1 - < 2.5
mectin B1a and avermectin B1b)		Acute Tox. 1; H330	
(ISO)	606-143-00-0	Acute Tox. 3; H311	
		Repr. 2; H361fd	
		STOT RE 1; H372	
		(Central nervous	
		system)	
		Aquatic Acute 1;	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

Version 4.1	Revision Date: 28.09.2024	SDS Number: 6029721-00013		
			H400 Aquatic Chronic 1; H410	
			M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000	
			specific concentration limit STOT RE 1; H372 >= 5 % STOT RE 2; H373 0.5 - < 5 %	
2,6-D	i-tert-butyl-p-cresol	128-37-0 204-881-4	Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	>= 0.25 - < 1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 6029721-00013 Date of first issue: 10.06.2020 4.1

> Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks Harmful if inhaled.

May cause damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- :

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 μg/m3 (OEB 3)	Internal
		Wipe limit	150 µg/100 cm²	Internal
2,6-Di-tert-butyl-p- cresol	128-37-0	OELV - 8 hrs (TWA)	2 mg/m3	IE OEL

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
2,6-Di-tert-butyl-p- cresol	Workers	Inhalation	Long-term systemic effects	3.5 mg/m3
	Workers	Dermal	Long-term systemic effects	0.5 mg/kg bw/day

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Consumers	Inhalation	Long-term systemic effects	0.86 mg/m3
Consumers	Dermal	Long-term systemic effects	0.25 mg/kg bw/day
Consumers	Ingestion	Long-term systemic effects	0.25 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
2,6-Di-tert-butyl-p-cresol	Fresh water	0.199 µg/l
	Intermittent use/release	0.02 µg/l
	Marine water	0.02 µg/l
	Sewage treatment plant	0.17 mg/l
	Fresh water sediment	0.0996 mg/kg dry
		weight (d.w.)
	Marine sediment	0.00996 mg/kg
		dry weight (d.w.)
	Soil	0.04769 mg/kg
		dry weight (d.w.)
	Oral (Secondary Poisoning)	8.33 mg/kg food

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : light yellow

Odour : characteristic

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

265 °C

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : 213.2 °C

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Relative density : No data available

Density : No data available

Relative vapour density : 0.90 - 0.91

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact

Ingestion Eye contact

Acute toxicity

Harmful if inhaled.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 2.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg

Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg

LD50 (Rabbit): 2,000 mg/kg

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg

Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : Mild eye irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximisation Test Exposure routes : Skin contact

Result : Not a skin sensitizer.

2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact Species : Humans : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Result: negative

Test Type: Alkaline elution assay

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Reproductive toxicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: NOAEL: 0.12 mg/kg body

weight

Result: Fetotoxicity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight Developmental Toxicity: NOAEL: 0.2 mg/kg body weight

Result: Cleft palate

Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: LOAEL: 2 mg/kg body weight Result: Cleft palate, Teratogenic effects, Reduced embryonic

survival

Remarks: Adverse developmental effects were observed

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1.6 mg/kg body weight

Result: Teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal experi-

ments.

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Application Route: Ingestion

Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes : Ingestion

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentra-

tions of 100 mg/kg bw or less.

Repeated dose toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 6029721-00013 Date of first issue: 10.06.2020

Exposure time : 14 Weeks

Target Organs : Central nervous system

2,6-Di-tert-butyl-p-cresol:

Species : Rat
NOAEL : 25 mg/kg
Application Route : Ingestion
Exposure time : 22 Months

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous

system effects, Salivation, tearing

SECTION 12: Ecological information

12.1 Toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l

Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l

Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l

Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l

Exposure time: 96 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 0.022 µg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 μg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 100

mg/

Exposure time: 72 h

M-Factor (Acute aquatic tox-

icity)

10,000

Toxicity to microorganisms : EC50 : > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.52 µg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.03 µg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

NOEC: 0.0035 µg/l Exposure time: 28 d

Species: Mysidopsis bahia (opossum shrimp)

M-Factor (Chronic aquatic

toxicity)

10,000

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0.57 mg/l

Exposure time: 96 h

Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.48 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- : 1

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

icity)

Toxicity to microorganisms : EC50 : > 10,000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.053 mg/l Exposure time: 30 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.316 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

M-Factor (Chronic aquatic

toxicity)

opecies. Daprilla magna (Water nea

12.2 Persistence and degradability

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

2,6-Di-tert-butyl-p-cresol:

Biodegradability : Result: Not readily biodegradable.

1

Biodegradation: 4.5 % Exposure time: 28 d

Method: OECD Test Guideline 301C

12.3 Bioaccumulative potential

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-

octanol/water

log Pow: 4

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n-

octanol/water

log Pow: 5.1

12.4 Mobility in soil

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environ: log Koc: > 3.6

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 6029721-00013 Date of first issue: 10.06.2020

mental compartments

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

14.3 Transport hazard class(es)

Class Subsidiary risks

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III Labels : 9

EmS Code : F-A, S-F

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

IATA (Cargo)

Packing instruction (cargo : 964

aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 964

ger aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 3

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not. Not applicable

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

E1

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

ENVIRONMENTAL

HAZARDS

Quantity 1 100 t

Not applicable

Not applicable

Not applicable

Quantity 2

200 t

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H300 : Fatal if swallowed.

H311 : Toxic in contact with skin.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 6029721-00013
 Date of first issue: 10.06.2020

H330 : Fatal if inhaled.

H361fd : Suspected of damaging fertility. Suspected of damaging the

unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 6029721-00013 Date of first issue: 10.06.2020

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Acute Tox. 4 H332 Calculation method STOT RE 2 H373 Calculation method Aquatic Acute 1 H400 Calculation method Aquatic Chronic 1 H410 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN